explore -WSS

explore

author：knowledge 2025-10-01 14:37:51 - browse：6859

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FDA gives detailed accounting of AI

WSS

How housing is health care on Long Island

Studies point to risks of excluding people with obesity from drug trials

FDA panel endorses Alnylam’s heart drug — after picking it apart

First Opinion Podcast: Long Covid needs a new approach

Pig kidney works a record two months in donated body

Food makers tried to stack nutrition panel with preferred experts

hotspot

explore

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

A common UTI test for kids haunts adults as a traumatic 'nightmare'

United colonoscopy coverage change 'may cost lives,' doctors say

The EU Joint Clinical Assessment needs to live up to its promise

Medicare details structure of new drug price negotiation program

UnitedHealth’s board chair also owns a personal investment firm

Walensky prepares to leave CDC — and Congress — behind

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Guidelines to prevent youth baseball injuries need more muscle

STAT Summit: Michael J. Fox on progress in Parkinson's research

hotspot

Studies point to risks of excluding people with obesity from drug trials

STAT Summit: Biotech founders on deal

New weight loss drugs vying to be the next Wegovy or Mounjaro

WATCH: Why do bright lights make us see spots?

IRA could hurt research into orphan drugs for rare diseases

First Opinion Podcast: Long Covid needs a new approach

entertainment

knowledge

focus

leisure time